MedPath

Ioversol

Generic Name
Ioversol
Brand Names
Optiray
Drug Type
Small Molecule
Chemical Formula
C18H24I3N3O9
CAS Number
87771-40-2
Unique Ingredient Identifier
N3RIB7X24K
Background

Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol, enhances the contrast between vessels in the path of the flow of the contrast medium and normal tissue, allowing the visualization of internal structures. Ioversol is a highly hydrophilic agent considered to be generally safe; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol, which is only indicated for intra-arterial and intravenous use.

Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left ventriculography.

Indication

As the product Optiray 300, the intra-arterial use of ioversol is indicated for cerebral arteriography and peripheral arteriography in adults, while its intravenous use is indicated for CT imaging of the head and body, venography, and intravenous excretory urography in adults.

As the product Optiray 320, the intra-arterial use of ioversol is indicated for cerebral arteriography, peripheral arteriography, visceral and renal arteriography, aortography, coronary arteriography, and left ventriculography in adults, and angiocardiography in pediatic patients. The intravenous use of this product is indicated for CT imaging of the head and body, venography, and intravenous excretory urography in adults and CT imaging of the head and body, and intravenous excretory urography in pediatric patients.

As the product Optiray 350, the intra-arterial use of ioversol is indicated for peripheral arteriography coronary arteriography, and left ventriculography in adults, and angiocardiography in pediatic patients. The intravenous use of this product is indicated for CT imaging of the head and body, venography, intravenous excretory urography, and intravenous digital subtraction angiography (IV-DSA) in adults and CT imaging of the head and body, and intravenous excretory urography in pediatric patients.

Associated Conditions
-
Associated Therapies
-

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media

Phase 4
Withdrawn
Conditions
Hypothyroidism
Interventions
First Posted Date
2018-08-15
Last Posted Date
2022-04-20
Lead Sponsor
GE Healthcare
Registration Number
NCT03631771

Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

Early Phase 1
Completed
Conditions
Myelodysplastic Syndromes
Leukemia, Myeloid, Acute
Leukemia, Myelogenous, Chronic
Multiple Myeloma
Interventions
Radiation: Dynamic contrast-enhanced computed tomography
Drug: Ioversol
First Posted Date
2014-04-17
Last Posted Date
2015-06-11
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
21
Registration Number
NCT02117115
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath